Drug Trial Radar · NCT06438367
TGRX-326 Pharmacokinetic Mass Balance
Last checked: Nov 19, 2026Latest source record: Feb 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Jun 26, 2024
Primary completion
Jul 8, 2024
Study completion Jul 21, 2024
Sponsor
- Lead sponsor
- Shenzhen TargetRx Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- The First Affiliated Hospital of Soochow University
- First posted
- May 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a pharmacokinetic study for TGRX-326 on mass balance to evaluate distribution, metabolism and excretion of TGRX-326, an ALK inhibitor indicated for treatment of Non-small cell lung cancer.
Conditions
- Non Small Cell Lung Cancer
Interventions
[14C]TGRX-326Drug
Healthy subjects will be given TGRX-326 60 mg orally on day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Urine radioactivityTime frame: Day-1 (day before dosing), Day 1 to Day 18 after dosing
- Fecal radioactivityTime frame: Day-1 (day before dosing), Day 1 to Day 18 after dosing
- Plasma AUC (Area under curve) percentageTime frame: Day-1 (day before dosing), Day 1 to Day 18 after dosing
- Urine %DoseTime frame: Day-1 (day before dosing), Day 1 to Day 18 after dosing
- Fecal %DoseTime frame: Day-1 (day before dosing), Day 1 to Day 18 after dosing
- Plasma CmaxTime frame: Day-1 (day before dosing), Day 1 to Day 18 after dosing
- Plasma TmaxTime frame: Day-1 (day before dosing), Day 1 to Day 18 after dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.